# **Does This Adult Patient Have Septic Arthritis?**

| Mary E. Margaretten, MD  |
|--------------------------|
| Jeffrey Kohlwes, MD, MPH |
| Dan Moore, PhD           |
| Stephen Bent, MD         |

#### **CLINICAL SCENARIO**

#### Case 1

A 48-year-old woman with a history of rheumatoid arthritis who has been treated with long-term, low-dose prednisone presents to the emergency department with a 2-day history of a red, swollen left knee that is painful to touch. She reports no prior knee swelling and no recent trauma or knee surgery, illegal drug use, rash, uveitis, or risky sexual behavior. On examination, she is afebrile and has a left knee effusion. Her peripheral white blood cell (WBC) count is 11 000/µL and her erythrocyte sedimentation rate (ESR) is 55 mm/h. An arthrocentesis is performed and initial laboratory test results show a negative Gram stain, a synovial fluid WBC count of 48 000/ µL, and the fluid culture is pending. What is the likelihood of septic arthritis in this patient?

#### Case 2

An 81-year-old man with dietcontrolled diabetes mellitus and hypertension presents to the general medicine clinic with a painful left ankle. He reports difficulty walking for the past 2 days and his left ankle is exquisitely tender to touch. When he had pain in his ankle previously, another physi-

#### See also Patient Page.

CME available online at www.jama.com

**Context** In patients who present with an acutely painful and swollen joint, prompt identification and treatment of septic arthritis can substantially reduce morbidity and mortality.

**Objective** To review the accuracy and precision of the clinical evaluation for the diagnosis of nongonococcal bacterial arthritis.

**Data Sources** Structured PubMed and EMBASE searches (1966 through January 2007), limited to human, English-language articles and using the following Medical Subject Headings terms: *arthritis, infectious, physical examination, medical history taking, diagnostic tests,* and *sensitivity and specificity.* 

**Study Selection** Studies were included if they contained original data on the accuracy or precision of historical items, physical examination, serum, or synovial fluid laboratory data for diagnosing septic arthritis.

**Data Extraction** Three authors independently abstracted data from the included studies.

Data Synthesis Fourteen studies involving 6242 patients, of whom 653 met the gold standard for the diagnosis of septic arthritis, satisfied all inclusion criteria. Two studies examined risk factors and found that age, diabetes mellitus, rheumatoid arthritis, joint surgery, hip or knee prosthesis, skin infection, and human immunodeficiency virus type 1 infection significantly increase the probability of septic arthritis. Joint pain (sensitivity, 85%; 95% confidence interval [CI], 78%-90%), a history of joint swelling (sensitivity, 78%; 95% CI, 71%-85%), and fever (sensitivity, 57%; 95% CI, 52%-62%) are the only findings that occur in more than 50% of patients. Sweats (sensitivity, 27%; 95% CI, 20%-34%) and rigors (sensitivity, 19%; 95% CI, 15%-24%) are less common findings in septic arthritis. Of all laboratory findings readily available to the clinician, the 2 most powerful were the synovial fluid white blood cell (WBC) count and percentage of polymorphonuclear cells from arthrocentesis. The summary likelihood ratio (LR) increased as the synovial fluid WBC count increased (for counts <25 000/µL: LR, 0.32; 95% CI, 0.23-0.43; for counts ≥25 000/µL: LR, 2.9; 95% CI, 2.5-3.4; for counts >50 000/µL: LR, 7.7; 95% CI, 5.7-11.0; and for counts >100 000/ µL: LR, 28.0; 95% CI, 12.0-66.0). On the same synovial fluid sample, a polymorphonuclear cell count of at least 90% suggests septic arthritis with an LR of 3.4 (95% CI, 2.8-4.2), while a polymorphonuclear cell count of less than 90% lowers the likelihood (LR, 0.34; 95% CI, 0.25-0.47).

**Conclusions** Clinical findings identify patients with peripheral, monoarticular arthritis who might have septic arthritis. However, the synovial WBC and percentage of polymorphonuclear cells from arthrocentesis are required to assess the likelihood of septic arthritis before the Gram stain and culture test results are known.

JAMA. 2007;297:1478-1488

www.jama.com

Author Affiliations: Division of Rheumatology (Dr Margaretten), Prime Program, Department of Medicine, University of California, San Francisco, and Department of Medicine, San Francisco Veterans Administration Medical Center (Drs Kohlwes and Bent), and Department of Epidemiology and Biostatistics, University of California, San Francisco (Dr Moore). Corresponding Author: Mary E. Margaretten, MD, Division of Rheumatology, U-384, University of California, 533 Parnassus Ave, San Francisco, CA 94143-0633 (mary.margaretten@ucsf.edu).

The Rational Clinical Examination Section Editors: David L. Simel, MD, MHS, Durham Veterans Affairs Medical Center and Duke University Medical Center, Durham, NC; Drummond Rennie, MD, Deputy Editor, JAMA.

1478 JAMA, April 4, 2007-Vol 297, No. 13 (Reprinted)

cian told him he had gout. On examination, he has a temperature of 38.2°C. By visual inspection, there is erythema and swelling over the dorsal aspect of the midfoot and ankle. Direct pressure over the ankle confirms extreme tenderness and swelling. What is the yield of arthrocentesis in detecting septic arthritis in this patient with presumptive gout?

#### WHY IS THE DIAGNOSIS OF SEPTIC ARTHRITIS IMPORTANT?

Infection, crystal-induced disease, osteoarthritis, trauma, and a variety of systemic diseases can create a painful, swollen peripheral joint. Nongonococcal bacterial arthritis is possibly the most dangerous and destructive type of acute arthritis and is the focus of this review. Promptly distinguishing nongonococcal septic arthritis from other causes of monoarthritis is important because septic arthritis can be devastating. Within days of onset, septic arthritis destroys cartilage.<sup>1,2</sup> The mortality rate for in-hospital septic arthritis ranges from 7% to 15%, despite antibiotic use.3-8 The incidence of bacterial arthritis has been reported in Scandinavia and Australia at 5.7 to 9 per 100 000 person-years and in England at 1 in 49 000 per 100 000 person-years, with increased incidence in patients with rheumatoid arthritis and joint prostheses.<sup>6,9,10</sup> Patients with rheumatoid arthritis or joint prostheses have an increased risk of septic arthritis, but distinguishing infection from underlying arthritides creates diagnostic challenges and a heightened urgency.

Although gonococcal arthritis is the most common strain of infectious arthritis,<sup>11</sup> it creates less morbidity and has a different clinical presentation. With gonococcal arthritis, women are affected 2 to 3 times more frequently than men, and a migratory tenosynovitis often accompanies the arthritis.<sup>12</sup> The Gram stain of the synovial fluid is positive in less than 10% of patients, and the test result of synovial fluid culture is often negative.<sup>13</sup> Because the

response to therapy is usually rapid and complete, this form of infectious arthritis is much less destructive than nongonococcal arthritis.<sup>14</sup>

When challenged with a patient who has a painful, swollen joint, a clinician must accurately estimate the probability of septic arthritis. This probability directs the physician in further diagnostic testing and treatment. Our goal is to determine the diagnostic value of the history, physical examination, and routine laboratory testing for identifying patients with septic arthritis. We include routine laboratory test results that are rapidly available because the results must be interpreted in light of the clinical findings.

#### Pathogenesis

Initially, bacteria enter the joint and deposit in the synovial membrane, which leads to an acute inflammatory response. Synovial tissue has no limiting basement membrane; therefore, bacterial organisms can easily enter the synovial fluid and create the characteristic purulent joint. Any microbial pathogen can cause septic arthritis, although staphylococci and streptococci are the most common of the nongonococcal bacterial isolates.<sup>3,5,6,8,15,16</sup> In the majority of cases, septic arthritis is monoarticular and occurs most commonly in large peripheral joints, such as the knee, which accounts for approximately 50% of cases.<sup>17,18</sup> The diagnosis for nongonococcal septic arthritis is confirmed by positive synovial fluid Gram stain or culture.

#### **Clinical Presentation**

Many conditions including crystal arthritis and systemic diseases, such as rheumatoid arthritis, can present with fever, joint swelling, pain, and stiffness,<sup>2,12,19-23</sup> mimicking the clinical presentation of septic arthritis. The differential diagnosis of an acute monoarticular arthritis is shown in BOX 1. Several historical features, symptoms, and signs have been associated with acute septic arthritis and may be useful as analytical tests; however, the diagnostic valBox 1. Differential Diagnosis for Acute Monoarthritis\*

Infection (bacterial, fungal, mycobacterial, viral, spirochete) Rheumatoid arthritis Gout Pseudogout Apatite-related arthropathy Reactive arthritis Systemic lupus erythematosus Lyme arthritis Sickle cell disease Dialysis-related amyloidosis Transient synovitis of the hip Plant thorn synovitis Metastatic carcinoma Pigmented villonodular synovitis Hemarthrosis Neuropathic arthropathy Osteoarthritis Intra-articular injury (fracture, meniscal tear, osteonecrosis) \*Adapted from Klippel et al.18

ues of these tests have not been established. The classic presentation of septic arthritis is an acutely swollen, painful joint with limited range of motion. Chills and fever are common but may be absent. When septic arthritis is suspected, arthrocentesis is mandatory. If an overlying cellulitis is present, the physician should perform the arthrocentesis while attempting to avoid percutaneous puncture of infected skin. Some clinicians favor proceeding with arthrocentesis through a cellulitic area when no other approach is possible. The synovial fluid should be sent for WBC count with differential, Gram stain, and culture to confirm the diagnosis and help guide treatment. Radiographs are usually normal early in the disease or are nonspecific.<sup>24</sup> Even the changes for septic arthritis by magnetic resonance imaging are imprecise and can be observed in noninfectious inflammatory arthropathies.25

## Box 2. Predetermined Criteria for the Quality of Evidence in Primary Studies

#### Study Quality

Score 1: Study includes consecutive patients with both negative and positive test results. No application of established clinical criteria for septic arthritis exists as an inclusion criterion. Patients require positive synovial fluid culture, Gram stain, blood culture, or clinical response to antibiotics to be classified as having septic arthritis.

Score 2: Study includes consecutive patients with both negative and positive results. Patients are classified based on both the presence of predefined established clinical criteria and positive synovial fluid culture, Gram stain, blood culture, or clinical response to antibiotics.

Score 3: Study of a nonconsecutive sample of patients with both negative and positive test results. Patients require positive synovial fluid culture, Gram stain, blood culture, or clinical response to antibiotics to be classified as having septic arthritis.

Score 4: A series of consecutive patients with septic arthritis proven by synovial culture, Gram stain, or clinical response to antibiotics.

Score 5: A random sample of patients with a clinical diagnosis of septic arthritis. No use of established criteria. Patients require positive synovial fluid culture, Gram stain, blood culture, or clinical response to antibiotics to be classified as having septic arthritis.

#### Level of Evidence

Level I: Independent, blind comparison of symptoms or signs with a gold standard among a large number (>50) of consecutive patients suspected of having septic arthritis.

Level II: Independent, blind comparison of symptoms or signs with a gold standard among a small number ( $\leq$ 50) of consecutive patients suspected of having septic arthritis.

Level III: Independent, blind comparison of symptoms or signs with a gold standard in nonconsecutive patients OR in patients known to have septic arthritis.

Level IV: Nonindependent comparison of symptoms or signs with a gold standard among samples of patients who obviously have septic arthritis plus, perhaps, healthy individuals.

Level V: Nonindependent comparison of symptoms or signs with a gold standard of uncertain validity (which may even incorporate the sign or symptom result in its definition) among samples of patients plus, perhaps, healthy individuals.

#### METHODS Search Strategy and Quality Literature Review

We searched the English-language medical literature from 1966 to January 2007 to identify articles that reported the diagnostic value of the history, physical examination, blood, or synovial fluid laboratory test results for distinguishing septic arthritis from other conditions. The search strategy used the following Medical Subject Headings (MeSH): arthritis, infectious, physical examination, medical history taking, diagnostic tests, and sensitivity and specificity, combined with the MeSH terms: arthritis, infectious or arthritis, gouty and synovial fluid, and arthritis, infectious AND (risk\* [title/ abstract] OR risk\* [MeSH:noexp] OR risk\* [MeSH:noexp] OR cohort studies [MeSH terms] OR group\* [text word], both limited to human, Englishlanguage articles. We also searched EMBASE using similar MeSH terms. Finally, we reviewed the references and citations from these articles to identify other relevant articles. The complete search strategy is available from the authors by request.

#### **Data Abstraction**

One of the authors (M.E.M.) initially screened the titles and abstracts of the search results. Three of the authors (J.K., S.B., and M.E.M.) then independently reviewed and abstracted data from articles identified as relevant. Differences in assessment were discussed and resolved by consensus.

Studies were included if they described patients who presented with an acutely painful or swollen joint and contained original data on accuracy and precision of the history and/or physical examination and/or laboratory data in diagnosing septic arthritis. We included laboratory data that were readily available to the bedside physician so that they could be used in clinical decision making. Articles were excluded if they did not include a gold standard measure for the diagnosis of septic arthritis. Although synovial fluid culture is considered the gold standard test for evaluating the presence of septic arthritis, it is an imperfect gold standard with reported sensitivities of only 75% to 95%.13 Therefore, we also included studies that used gold standard tests of positive Gram stain, positive blood cultures, no organism isolated but macroscopic pus aspirated from joint, or response to antibiotics.

We classified the quality of evidence in each study by 2 separate methods (Box 2). To evaluate clinical symptoms and signs of septic arthritis, we used criteria that included consecutive vs nonconsecutive samples, inclusion of patients with the diagnosis of only septic arthritis vs other joint disease, and the requirement of positive synovial culture, Gram stain, blood culture, or response to antibiotics for all patients labeled as having nongonococcal septic arthritis.<sup>26</sup> Also, we graded the quality of each study using a classification scheme for levels of evidence used previously for The Rational Clinical Examination series.<sup>27</sup>

#### **Statistical Methods**

The primary outcome measures of this study were the likelihood ratios (LRs) for all symptoms or signs used to dis-

1480 JAMA, April 4, 2007-Vol 297, No. 13 (Reprinted)

tinguish septic arthritis from other causes of an acutely painful or swollen joint. We used data from the identified articles to calculate the sensitivity, specificity, and positive and negative LR, as well as the summary LR. The positive LR is a measure of how strongly a positive result increases the odds of disease, and the negative LR is a measure of how well a negative result decreases the odds of a disease. To calculate summary LRs, we used a random effects model, a conservative summary measure in that it provides broad confidence intervals (CIs) that display the heterogeneity of results. Microsoft Excel 2003 (Microsoft Corp, Redmond, Wash) was used for all statistical analyses. P<.05 was considered statistically significant.

#### Accuracy of Signs and Symptoms

Studies used varying definitions for fever ranging from 37.5°C to 38.0°C and whether fever occurred at either presentation or during hospital course. We defined fever as absent or present based on the individual article definitions. The studies presented used the definition for elevated peripheral WBC count as more than 10 000/µL, elevated ESR as more than 30 mm/h, and markedly elevated C-reactive protein (CRP) as more than 100 mg/L. A reduction in synovial fluid glucose was based on individual article definitions and ranged from a serum/synovial fluid glucose ratio of less than 0.5 or 0.75, a synovial fluid glucose level of less than 1.5 mmol/mL, or both. To convert synovial fluid glucose to g/dL, divide by 0.0555.

#### RESULTS

The PubMed searches identified 251 articles and the EMBASE search identified an additional 399 articles for a total of 650 articles (FIGURE). Studies were judged irrelevant if they did not include original data on the accuracy or precision of history, physical examination, and/or routine laboratory test results in diagnosing septic arthritis. Six hundred eighteen articles were excluded based on review of their abstracts, leaving 32 articles for full manuscript review. There were 13 studies that reviewed patients with infected joints but did not provide sufficient data and, therefore, could not be included in our study.<sup>5,7,8,10,28-36</sup> Five studies did not evaluate clinical tests of interest.37-41 Thus, the final data shown in TABLE 1 are based on 14 studies that met all the inclusion criteria<sup>3,6,15,42-51</sup> and included 6242 patients, of whom 653 were diagnosed with septic arthritis. The studies took place between 1979 and 2003, and ranged in size from 41 to 4889 patients. However, 1 study<sup>42</sup> evaluating risk factors involved the majority of the patients. The other 7 studies43-48 included a total of 1353 patients, ranging from 41 to 362 patients and assessed symptoms, signs, serum laboratory values, and synovial fluid for the diagnosis of septic arthritis. Although we did not exclude studies of gonococcal arthritis, the difficulty of confirming gonococcal arthritis by Gram stain or culture (gold standard) meant that only a few of these patients were included in the retained studies.

The patients in the 14 studies were all adults and included patients in rheumatology clinics, those patients presenting to the emergency department, or hospitalized patients. The quality scores were relatively low, with only 3 studies attaining a level 1 score. Most studies used an adequate gold standard.

#### Prevalence of Septic Arthritis Among Patients With Acute Monoarthritis

Two of the studies were prospective studies enrolling patients with acutely swollen, painful joints, and were therefore useful for estimating a pretest probability of septic arthritis. In the prospective study by Shmerling et al,<sup>46</sup> 8 (8%) of 100 consecutive patients evaluated for 1 or more painful, swollen joints between 1987 and 1988 at Beth Israel Hospital in Boston, Mass, had septic arthritis. In the prospective study by Jeng et al,<sup>48</sup> 20 (27%) of 75 patients presenting to the emergency department with acute arthritis between 1993 and 1995 in





Taiwan were found to have septic arthritis. Thus, the range of reported prevalence from 2 prospective studies of septic arthritis in patients who presented with an acutely painful and swollen joint is 8% to 27%.<sup>46,48</sup> We report the prevalence estimate as a range rather than a summary because the risks are significantly different ( $\chi^2$ test, *P*<.001), and the patient populations were from 2 different clinical settings.

#### **Risk Factors for Septic Arthritis**

TABLE 2 shows abstracted sensitivity and specificity data and calculated positive and negative LRs for the risk factors, signs, and serum laboratory values to aid the diagnosis of acute septic arthritis. Two studies examined risk factors for diagnosing septic arthritis among patients with an acute inflammatory arthritis. One prospective cohort<sup>42</sup> from the Netherlands found that the likelihood of septic arthritis increases with age older than 80 years (LR, 3.5; 95% CI, 1.8-7.0), diabetes mellitus (LR, 2.7; 95% CI, 1.0-6.9), rheumatoid arthritis (LR, 2.5; 95% CI, 2.0-3.1), recent joint surgery (LR, 6.9; 95% CI, 3.8-12.0), hip or knee prosthesis (LR, 3.1; 95% CI, 2.0-4.9), skin infection (LR, 2.8; 95% CI, 1.7-4.5), and skin infection in combination with joint prosthesis (LR, 15.0; 95% CI, 8.1-28.0). The second study, 43 a case-control study in Rwanda (in which the prevalence of human immu-

nodeficiency virus [HIV] infection is 30%), assessed only the diagnostic value of HIV-1 and found that infection

Table 1. Studies of the Performance of Clinical Findings in Diagnosing Septic Arthritis

increases the likelihood of septic arthritis minimally (LR, 1.7; 95% CI, 1.0-2.8).

**Symptoms of Septic Arthritis** We found only 6 studies<sup>3,6,15,49-51</sup> that tested the sensitivity of symptoms for

| Sourco                                      | Study<br>Quality/<br>Level of | Location           | No. of                             | Mean                                   | Study Docian  | Case Selection   | Control Solootion  | Prevalence<br>of Septic                          | Clinical Finding  |
|---|-------------------------------|--------------------|------------------------------------|--|---|--|--|--|---|
| Kaandorp et<br>al, <sup>42</sup> 1995       | 1/l                           | The<br>Netherlands | 4889<br>(total)<br>37<br>(cases)   | 65                                     | Prospective<br>cohort from<br>outpatient<br>rheumatology<br>clinics                     | Blood culture and<br>synovial fluid or<br>strong clinical<br>suspicion*  | Control patients were<br>members of<br>cohort who did<br>not develop septic<br>arthritis   | 0.25†  | Various risk factors  |
| Saraux et<br>al, <sup>43</sup> 1997         | 2/11                          | Rwanda             | 24<br>(cases)<br>135<br>(controls) | 30                                     | Prospective<br>case-control<br>series   | Hospitalized patients<br>with inflammatory<br>joint disease  | Hospitalized patients<br>with malaria  | 0.50<br>(HIV positive)<br>0.25 (HIV<br>negative) | HIV-1 antibody test<br>confirmed with<br>immunoassay or<br>Western blot   |
| Söderquist<br>et al, <sup>44</sup><br>1998  | 3/111                         | Sweden             | 54<br>(cases)<br>34<br>(controls)  | 72<br>(cases)<br>78<br>(controls)      | Retrospective<br>case-control<br>series   | Hospitalized patients Crystal plus synovial<br>with blood culture fluid<br>and synovial fluid                      |  | Not reported                                     | C-reactive protein,<br>synovial WBC<br>count, glucose,<br>TNF-α,<br>granulocyte<br>colony-<br>stimulating factor,<br>IL-6, IL-8 |
| Krey et al,45<br>1979                       | 3/IV                          | United<br>States   | 50<br>(cases)<br>312<br>(controls) | Not<br>reported                        | Case-control<br>series  | Blood culture and synovial fluid   | Crystal plus synovial<br>fluid or diagnosis<br>of rheumatoid<br>arthritis‡   | Not reported                                     | Synovial WBC<br>count,<br>percentage of<br>polymorpho-<br>nuclear cells   |
| Shmerling et<br>al, <sup>46</sup> 1990      | 1/1                           | United<br>States   | 100<br>(total)<br>8 (cases)        | Not<br>reported                        | Prospective<br>case series  | Blood culture plus<br>synovial fluid and<br>blood culture<br>indicated<br>probable septic<br>arthritis§            | Crystal plus synovial<br>fluid, diagnosis of<br>rheumatoid<br>arthritis,‡<br>osteoarthritis,<br>trauma, or<br>miscellaneous<br>(sickle cell, SLE,<br>MCTD, hepatitis B<br>positive), no<br>diagnosis | 8  | Synovial WBC<br>count,<br>percentage of<br>polymorpho-<br>nuclear cells,<br>glucose, protein,<br>lactate<br>dehydrogenase       |
| Shmerling et<br>al, <sup>46</sup> 1990      | 4/111                         | United<br>States   | 119<br>(total)<br>27<br>(cases)    | Not<br>reported                        | Retrospective<br>and<br>prospective<br>case series                                      | Blood culture plus<br>synovial fluid and<br>blood culture<br>indicated<br>probable septic<br>arthritis§            | Crystal plus synovial<br>fluid, diagnosis of<br>rheumatoid<br>arthritis,‡<br>osteoarthritis,<br>trauma,<br>miscellaneous<br>(sickle cell, SLE,<br>MCTD, hepatitis B<br>positive), no<br>diagnosis    | Not reported                                     | Synovial WBC<br>count,<br>percentage of<br>polymorpho-<br>nuclear cells,<br>glucose, protein,<br>lactate<br>dehydrogenase       |
| Kortekangas<br>et al, <sup>47</sup><br>1992 | 3/111                         | Finland            | 28<br>(cases)<br>52<br>(controls)  | 57<br>(cases)<br>36 & 60<br>(controls) | Retrospective<br>case-control<br>series   | Blood culture and<br>synovial fluid  | Blood culture<br>indicated arthritis,<br>diagnosis of<br>rheumatoid<br>arthritis‡ or<br>reactive arthritis   | 35   | Fever, synovial<br>WBC count,<br>percentage of<br>polymorpho-<br>nuclear cells  |
| Jeng et al, <sup>48</sup><br>1997           | 1/1                           | Taiwan             | 75 (total)<br>20<br>(cases)        | 55                                     | Prospective<br>case series  | Patients in<br>emergency<br>department with<br>acute arthritis and<br>positive synovial<br>cultures                | Crystal plus synovial<br>fluid, diagnosis of<br>rheumatoid<br>arthritis,‡<br>osteoarthritis,<br>reactive arthritis,<br>SLE   | 27   | Peripheral WBC<br>count,<br>erythrocyte<br>sedimentation<br>rate, synovial<br>TNF-a, IL-1, IL-6                                 |
| Gupta et al, <sup>3</sup><br>2001           | 4/111                         | Scotland           | 75                                 | 63                                     | Prospective<br>cohort from<br>11 hospitals<br>serving a<br>population of<br>2.3 million | Patients identified by<br>rheumatologists<br>or orthopedic<br>surgeons with<br>blood culture and<br>synovial fluid | Control patients were<br>members of<br>cohort who did<br>not develop septic<br>arthritis   | 0.0016†  | Symptoms (joint<br>pain, edema,<br>sweats, rigors)<br>and fever   |

1482 JAMA, April 4, 2007-Vol 297, No. 13 (Reprinted)

| Source                                     | Study<br>Quality/<br>Level of<br>Evidence | Location         | No. of<br>Patients | Mean<br>Age, y  | Study Design                 | Case Selection   | Control Selection   | Prevalence<br>of Septic<br>Arthritis, % | Clinical Finding  |
|--|---|------------------|--------------------|-----------------|------------------------------|--|---|---|---|
| Gupta et al, <sup>6</sup><br>2003          | 4/IV                                      | Scotland         | 82                 | 67              | Prospective<br>case series   | Patients identified by<br>rheumatologists,<br>orthopedic<br>surgeons, or<br>bacteriologists<br>with blood culture<br>plus synovial fluid<br>or blood culture<br>alone indicated<br>probable septic<br>arthritis§ | NA  | NA                                      | Symptoms (joint<br>pain, edema,<br>sweats, rigors)<br>and fever |
| McCutchan<br>et al, <sup>15</sup><br>1990  | 4/IV                                      | United<br>States | 41                 | 47              | Retrospective<br>case series | Hospitalized patients<br>with blood culture<br>and synovial fluid  | NA  | NA                                      | Fever   |
| Schlapbach<br>et al, <sup>49</sup><br>1990 | 5/IV                                      | Switzerland      | 43                 | 57              | Retrospective case series    | Hospitalized patients<br>with blood culture<br>and synovial fluid  | -Inspitalized patients NA<br>with blood culture<br>and synovial fluid |   | Rigors and fever  |
| Rosenthal et<br>al, <sup>50</sup> 1980     | 5/IV                                      | United<br>States | 63                 | 36              | Retrospective<br>case series | Hospitalized patients NA<br>with a diagnosis<br>of septic arthritis<br>and blood culture<br>plus synovial fluid<br>or positive blood<br>cultures   |   | NA                                      | Fever   |
| Deesomchok<br>et al, <sup>51</sup><br>1990 | 5/IV                                      | Thailand         | 101                | Not<br>reported | Retrospective<br>case series | Hospitalized patients<br>with a diagnosis<br>of septic arthritis<br>and blood culture<br>plus synovial fluid<br>or positive blood<br>cultures  | NA  | NA                                      | Rigors and fever  |

**Table 1.** Studies of the Performance of Clinical Findings in Diagnosing Septic Arthritis (cont)

Abbreviations: HIV, human immunodeficiency virus; IL, interleukin; MCTD, mixed connective tissue disease; NA, not applicable; SLE, systemic lupus erythematosus; TNF-α, tumor necrosis factor α; WBC, white blood cell.

\*Positive culture or direct identification of microorganisms in synovial fluid or tissue, or macroscopic pus produced by arthrocentesis or a clinical presentation of synovitis with rapidly progressive joint destruction without alternative explanation.

†Annual incidence (disease frequency in the study population over 1 year).

‡All patients with rheumatoid arthritis fulfilled the American College of Rheumatology criteria for classic or definite rheumatoid arthritis.

\$Probable septic arthritis includes patients partially treated with antibiotics, positive blood cultures, or clinical response to antibiotics.

All patients with reactive arthritis had purulent joint effusion with negative synovial cultures, but positive serology or bacteriology for Yersinia or Salmonella gastrointestinal infections, or Chlamydia urogenital infections.

diagnosing septic arthritis, and none that evaluated specificity (TABLE 3). Pain in the affected joint is present in 85% (95% CI, 78%-90%) of cases and a history of swelling is present in 78% (95% CI, 71%-85%) of cases. Other symptoms, such as sweats and rigors, are poorly sensitive at 27% (95% CI, 20%-34%) and 19% (95% CI, 15%-24%), respectively.

#### **Signs of Septic Arthritis**

Seven studies<sup>3,6,15,47,49-51</sup> show that fever occurs in more than 50% of patients (sensitivity, 57%; 95% CI, 52%-62%). One case-control study<sup>47</sup> of 80 patients evaluated fever as a physical examination finding in patients with either septic arthritis or other acute joint disease; 46% of patients with culture-

positive bacterial arthritis had a fever (temperature  $>37.5^{\circ}$ C. In the only study<sup>47</sup> that assessed the LR of fever, septic arthritis was less likely when the patient was febrile (LR, 0.67; 95% CI, 0.43-1.00). We found no additional studies that assessed other examination findings, such as tenderness to palpation, edema, or range of motion of the affected joint.

#### **Serum Laboratory Values**

An abnormal peripheral WBC count, ESR, and CRP were found to have limited diagnostic power for changing the pretest probability of septic arthritis, mostly due to their low specificity. In a prospective study<sup>48</sup> of 75 patients presenting to the emergency department with an acute monoarthritis, a peripheral WBC count of more than 10 000/µL increased the likelihood of septic arthritis minimally (LR, 1.4; 95% CI, 1.1-1.8). The same study showed that an ESR of more than 30 mm/h also increased the likelihood of septic arthritis minimally (LR, 1.3; 95% CI, 1.1-1.8).<sup>48</sup> Similarly, a retrospective case-control series demonstrated that a markedly elevated CRP of more than 100 mg/L increased the likelihood of septic arthritis slightly (LR, 1.6; 95% CI, 1.1-2.5).<sup>44</sup>

#### Synovial WBC Counts and Polymorphonuclear Cells

Progressively higher synovial WBC counts increase the likelihood of septic arthritis (for synovial WBC count  $<25\,000/\mu$ L: LR, 0.32; 95% CI, 0.23-0.43; for synovial WBC counts

©2007 American Medical Association. All rights reserved.

(Reprinted) JAMA, April 4, 2007–Vol 297, No. 13 1483

| Table 2. Likelihood Ratios for | or Risk Factors, Signs, a | and Serum Laborator | y Values |
|--------------------------------|---------------------------|---------------------|----------|
|--------------------------------|---------------------------|---------------------|----------|

| Source                             | Sensitivity,<br>%  | Specificity,<br>%  | Relative<br>Risk  | Likelihood Ratio<br>(95% Cl)  |  |  |
|------------------------------------|--|--|---|---|--|--|
|                                    |  |  |   | Positive  | Negative   |  |
|                                    |  |  |   |   |  |  |
| Kaandorp et al,42 1995             | 19   | 95   | 4.1   | 3.5 (1.8-7.0)   | 0.86 (0.73-1.00)   |  |
| Kaandorp et al,42 1995             | 12   | 96   | 2.8   | 2.7 (1.0-6.9)   | 0.93 (0.83-1.00)   |  |
| Kaandorp et al,42 1995             | 68   | 73   | 5.4   | 2.5 (2.0-3.1)   | 0.45 (0.32-0.72)   |  |
| Kaandorp et al,42 1995             | 24   | 96   | 8.4   | 6.9 (3.8-12.0)  | 0.78 (0.64-0.94)   |  |
| Kaandorp et al, <sup>42</sup> 1995 | 35   | 89   | 4.1   | 3.1 (2.0-4.9)   | 0.73 (0.57-0.93)   |  |
| Kaandorp et al, <sup>42</sup> 1995 | 32   | 88   | 3.6   | 2.8 (1.7-4.5)   | 0.76 (0.60-0.96)   |  |
| Kaandorp et al, <sup>42</sup> 1995 | 24   | 98   | 18  | 15.0 (8.1-28.0)   | 0.77 (0.64-0.93)   |  |
| Saraux et al,43 1997               | 79   | 50   | 3.2   | 1.7 (1.0-2.8)   | 0.47 (0.25-0.90)   |  |
| Kortekangas et al,47 1992          | 46   | 31   | NA  | 0.67 (0.43-1.00)  | 1.7 (1.0-3.0)  |  |
|                                    |  |  |   |   |  |  |
| Jeng et al,48 1997                 | 90   | 36   | NA  | 1.4 (1.1-1.8)   | 0.28 (0.07-1.10)   |  |
| Jeng et al,48 1997                 | 95   | 29   | NA  | 1.3 (1.1-1.8)   | 0.17 (0.20-1.30)   |  |
| Söderquist et al,44 1998           | 77   | 53   | NA  | 1.6 (1.1-2.5)   | 0.44 (0.24-0.82)   |  |
|                                    | Source           Kaandorp et al, <sup>42</sup> 1995           Kortekangas et al, <sup>47</sup> 1992           Jeng et al, <sup>48</sup> 1997           Jeng et al, <sup>48</sup> 1997           Söderquist et al, <sup>44</sup> 1998 | Source         Sensitivity,           Kaandorp et al, <sup>42</sup> 1995         19           Kaandorp et al, <sup>42</sup> 1995         12           Kaandorp et al, <sup>42</sup> 1995         68           Kaandorp et al, <sup>42</sup> 1995         68           Kaandorp et al, <sup>42</sup> 1995         24           Kaandorp et al, <sup>42</sup> 1995         35           Kaandorp et al, <sup>42</sup> 1995         32           Kaandorp et al, <sup>42</sup> 1995         24           Saraux et al, <sup>43</sup> 1997         79           Kortekangas et al, <sup>47</sup> 1992         46           Jeng et al, <sup>48</sup> 1997         95           Söderquist et al, <sup>44</sup> 1998         77 | Source         Sensitivity,<br>%         Specificity,<br>%           Kaandorp et al, <sup>42</sup> 1995         19         95           Kaandorp et al, <sup>42</sup> 1995         12         96           Kaandorp et al, <sup>42</sup> 1995         68         73           Kaandorp et al, <sup>42</sup> 1995         68         73           Kaandorp et al, <sup>42</sup> 1995         24         96           Kaandorp et al, <sup>42</sup> 1995         32         88           Kaandorp et al, <sup>42</sup> 1995         24         98           Kaandorp et al, <sup>42</sup> 1995         24         98           Saraux et al, <sup>43</sup> 1997         79         50           Kortekangas et al, <sup>47</sup> 1992         46         31           Jeng et al, <sup>48</sup> 1997         95         29           Söderquist et al, <sup>44</sup> 1998         77         53 | SourceSensitivity,<br>%Specificity,<br>%Relative<br>RiskKaandorp et al,42 199519954.1Kaandorp et al,42 199512962.8Kaandorp et al,42 199568735.4Kaandorp et al,42 199568735.4Kaandorp et al,42 199524968.4Kaandorp et al,42 199535894.1Kaandorp et al,42 199532883.6Kaandorp et al,42 1995249818Saraux et al,43 199779503.2Kortekangas et al,47 19924631NAJeng et al,48 19979529NASöderquist et al,44 19987753NA | Source         Sensitivity,<br>%         Specificity,<br>%         Relative<br>Risk         Existivity,<br>Positive           Kaandorp et al, <sup>42</sup> 1995         19         95         4.1         3.5 (1.8 - 7.0)           Kaandorp et al, <sup>42</sup> 1995         12         96         2.8         2.7 (1.0 - 6.9)           Kaandorp et al, <sup>42</sup> 1995         68         73         5.4         2.5 (2.0 - 3.1)           Kaandorp et al, <sup>42</sup> 1995         24         96         8.4         6.9 (3.8 - 12.0)           Kaandorp et al, <sup>42</sup> 1995         24         96         8.4         6.9 (3.8 - 12.0)           Kaandorp et al, <sup>42</sup> 1995         24         96         8.4         6.9 (3.8 - 12.0)           Kaandorp et al, <sup>42</sup> 1995         32         88         3.6         2.8 (1.7 - 4.5)           Kaandorp et al, <sup>42</sup> 1995         24         98         18         15.0 (8.1 - 28.0)           Kaandorp et al, <sup>43</sup> 1997         79         50         3.2         1.7 (1.0 - 2.8)           Kortekangas et al, <sup>47</sup> 1992         46         31         NA         0.67 (0.43 - 1.00)           Jang et al, <sup>48</sup> 1997         95         29         NA         1.4 (1.1 - 1.8)           Jeng et al, <sup>48</sup> 1997         95         29         NA         1.6 (1.1 - 2.5) |  |

Abbreviations: CI, confidence interval; HIV-1, human immunodeficiency virus type 1; NA, not applicable; WBC, white blood cell.

\*Defined as abnormal peripheral WBC count of more than 10 000/µL, elevated erythrocyte sedimentation rate of more than 30 mm/h, and elevated C-reactive protein of more than 100 mg/L.

| <b>Table 3.</b> Sensitivity of Symptoms and Signs* |                   |                            |  |  |  |  |
|--|-------------------|----------------------------|--|--|--|--|
| Variable   | No. of<br>Studies | Sensitivity, %<br>(95% Cl) |  |  |  |  |
| Joint pain   | 2                 | 85 (78-90)                 |  |  |  |  |
| History of joint edema                             | 2                 | 78 (71-85)                 |  |  |  |  |
| Fever  | 7                 | 57 (52-62)                 |  |  |  |  |
| Sweats   | 2                 | 27 (20-34)                 |  |  |  |  |
| Rigors   | 4                 | 19 (15-24)                 |  |  |  |  |

Abbreviation: Cl, confidence interval. \*With the exception of the study by Kortekangas et al,<sup>47</sup> the studies reviewed only included patients with septic

arthritis, which permits calculation of only sensitivity and not specificity or likelihood ratios.

≥25 000/µL: LR, 2.9; 95% CI, 2.5-3.4; for synovial WBC counts >50 000/ µL: LR, 7.7; 95% CI, 5.7-11.0; and for synovial WBC counts >100 000/µL: LR, 28.0; 95% CI, 12.0-66.0) (TABLE 4). Four studies show that polymorphonuclear cells of at least 90% is associated with septic arthritis.<sup>45-47</sup> When the percentage of polymorphonuclear cells is at least 90%, the likelihood of septic arthritis is increased (LR, 3.4; 95% CI, 2.8-4.2); and for polymorphonuclear cells less than 90%, the likelihood decreased (LR, 0.34; 95% CI, 0.25-0.47).

#### Other Serum and Synovial Markers of Inflammation

 TABLE 5 shows abstracted sensitivity

 and specificity data and calculated

 positive and negative LRs for other

synovial laboratory test results and markers of inflammation. Synovial glucose and protein were evaluated by Söderquist et al<sup>44</sup> in a retrospective case series and by Shmerling et al<sup>46</sup> in a prospective and combined prospective and retrospective case series. A low synovial fluid glucose was not sensitive in the 3 studies (64%, 38%, and 44%, respectively), and specificity was 85% for all 3 studies. Synovial fluid protein levels were determined in only 6 cases in each group, and no differences were found in the study by Söderquist et al. Similarly, elevated protein levels (>3.0 g/dL) were neither sensitive nor specific in the studies by Shmerling et al. The studies by Shmerling et al also looked at lactate dehydrogenase, which was 100% sensitive for septic arthritis but had poor specificity with only half the cases being septic arthritis, resulting in many false-positive test results.

#### COMMENT

Our systematic review of the literature shows that the quality of evidence describing risk factors, history, and physical examination for the diagnosis of septic arthritis is limited. Only 2 studies, a prospective cohort from outpatient clinics<sup>9</sup> and a case-control series of patients who were hospitalized,<sup>43</sup> assessed risk factors and identified age older than 80 years, diabetes mellitus, rheumatoid arthritis, recent joint surgery, hip or knee prosthesis and/or skin infection, and HIV-1 infection as important risk factors. Most of these risk factors were only useful when present (increasing the likelihood of septic arthritis) and did not substantially lower the likelihood of bacterial infection when they were absent.

Two studies show that joint pain and a history of joint swelling are reasonably sensitive for septic arthritis, but there are no studies addressing the specificity of these symptoms (Table 3). In clinical practice, it is well known that many monoarticular arthritides can present in such a manner. However, these 2 symptoms describe the relevant population in whom septic arthritis should be considered. The sensitivity of fever as a diagnostic test for nongonococcal bacterial arthritis was only 57%, indicating that almost half of patients with septic arthritis will not present with fever, and the absence of fever clearly does not rule out infection. Furthermore, given its poor specificity, the presence of fever does not help the clinician rule in septic

1484 JAMA, April 4, 2007-Vol 297, No. 13 (Reprinted)

| Table 4. Test Characteristics of | of Synovial Fluid Studies   |                  |     |                              |                  |  |  |
|----------------------------------|---|------------------|-----|------------------------------|------------------|--|--|
|                                  |   | Septic Arthritis |     |                              |                  |  |  |
|                                  |   | Concitivity      | 0   | Likelihood Ratio<br>(95% Cl) |                  |  |  |
|                                  | Source  | %                | %   | Positive                     | Negative         |  |  |
| WBCs >100 000/µL                 |   |                  |     |                              |                  |  |  |
|                                  | Söderquist et al, <sup>44</sup> 1998                                | 30               | 93  | 4.7 (1.1-20.0)               | 0.75 (0.59-0.96) |  |  |
|                                  | Krey et al, <sup>45</sup> 1979                                      | 40               | 99  | 42.0 (13.0-138.0)            | 0.61 (0.49-0.77) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (prospective)                   | 13               | 100 | 31.0 (1.1-914.0)             | 0.84 (0.64-1.10) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 19               | 100 | 37.0 (2.0-687.0)             | 0.81 (0.68-0.97) |  |  |
|                                  | Kortekangas et al,47 1992   | 25               | 98  | 12.0 (1.5-97.0)              | 0.77 (0.61-1.00) |  |  |
|                                  | Summary   | 29               | 99  | 28.0 (12.0-66.0)             | 0.71 (0.64-0.79) |  |  |
| WBCs >50 000/µL                  | Söderquist et al, <sup>44</sup> 1998                                | 58               | 74  | 2.2 (1.1-4.4)                | 0.57 (0.36-0.90) |  |  |
|                                  | Krey et al, <sup>45</sup> 1979                                      | 70               | 92  | 8.7 (5.7-13.0)               | 0.33 (0.22-0.51) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (prospective)                   | 50               | 97  | 15.0 (4.0-58.0)              | 0.52 (0.26-1.10) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 63               | 97  | 19.0 (6.0-62.0)              | 0.38 (0.23-0.63) |  |  |
|                                  | Kortekangas et al, <sup>47</sup> 1992                               | 53               | 86  | 3.8 (1.8-8.4)                | 0.54 (0.40-0.80) |  |  |
|                                  | Summary   | 62               | 92  | 7.7 (5.7-11.0)               | 0.42 (0.34-0.51) |  |  |
| WBCs >25 000/µL                  | Söderquist et al. <sup>44</sup> 1998                                | 73               | 58  | 1.7 (1.1-3.0)                | 0.47 (0.25-0.90) |  |  |
|                                  | Krev et al. <sup>45</sup> 1979                                      | 88               | 71  | 3.1 (2.5-3.8)                | 0.17 (0.08-0.36) |  |  |
|                                  | Shmerling et al. <sup>46</sup> 1990 (prospective)                   | 63               | 83  | 3.6 (1.8-7.3)                | 0.45 (0.17-1.10) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 70               | 83  | 4.0 (2.4-6.8)                | 0.36 (0.20-0.66) |  |  |
|                                  | Kortekangas et al, <sup>47</sup> 1992                               | 71               | 62  | 1.9 (1.2-2.9)                | 0.46 (0.24-0.87) |  |  |
|                                  | Summary   | 77               | 73  | 2.9 (2.5-3.4)                | 0.32 (0.23-0.43) |  |  |
| Polymorphonuclear cells ≥90%     |   |                  |     |                              |                  |  |  |
|                                  | Söderquist et al, <sup>44</sup> 1998                                | 92               | 78  | 4.2 (3.3-5.3)                | 0.10 (0.04-0.26) |  |  |
|                                  | Krey et al, <sup>45</sup> 1979                                      | 63               | 82  | 3.4 (1.7-6.4)                | 0.46 (0.18-1.20) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (prospective)                   | 58               | 83  | 3.3 (1.9-5.9)                | 0.51 (0.32-0.82) |  |  |
|                                  | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 57               | 68  | 1.8 (1.0-3.0)                | 0.63 (0.39-1.00) |  |  |
|                                  | Summary   | 73               | 79  | 3.4 (2.8-4.2)                | 0.34 (0.25-0.47) |  |  |

Abbreviations: CI, confidence interval; WBC, white blood cell.

#### Table 5. Other Synovial Fluid Laboratory Test Results

|                   |   | Sensitivity,<br>% | Specificity,<br>% | Likelihood Ratio<br>(95% Cl) |                  |  |
|-------------------|---|-------------------|-------------------|------------------------------|------------------|--|
|                   | Source  |                   |                   | Positive                     | Negative         |  |
| Low glucose*      |   |                   |                   |                              |                  |  |
| 0                 | Söderquist et al,44 1998  | 64                | 85                | 4.2 (1.4-13.0)               | 0.43 (0.24-0.78) |  |
|                   | Shmerling et al, <sup>46</sup> 1990 (prospective)                   | 38                | 85                | 2.5 (0.87-6.90)              | 0.74 (0.43-1.30) |  |
|                   | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 44                | 85                | 2.9 (1.5-5.6)                | 0.66 (0.46-0.94) |  |
|                   | Summary   | 51                | 85                | 3.4 (2.2-5.1)                | 0.58 (0.44-0.76) |  |
| Protein >3.0 g/dL |   |                   |                   |                              |                  |  |
| 0                 | Shmerling et al, <sup>46</sup> 1990 (prospective)                   | 50                | 46                | 0.93 (0.45-1.90)             | 1.10 (0.53-2.20) |  |
|                   | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 48                | 46                | 0.89 (0.55-1.40)             | 1.10 (0.68-1.80) |  |
|                   | Summary   | 48                | 46                | 0.90 (0.61-1.30)             | 1.10 (0.76-1.60) |  |
| LDH >250 U/L      |   |                   |                   |                              |                  |  |
|                   | Shmerling et al, <sup>46</sup> 1990 (prospective)                   | 100               | 51                | 1.9 (1.5-2.5)                | 0.11 (0.01-1.70) |  |
|                   | Shmerling et al, <sup>46</sup> 1990 (retrospective and prospective) | 100               | 50                | 1.9 (1.5-2.5)                | 0.09 (0.01-1.40) |  |
|                   | Summary   | 100               | 51                | 1.9 (1.5-2.5)                | 0.10 (0.00-1.60) |  |

Abbreviations: CI, confidence interval; LDH, lactate dehydrogenase. \*Defined in the different studies as serum/synovial fluid glucose ratio of less than 0.5 or 0.75, synovial fluid glucose level of less than 1.5 mmol/mL, or both. To convert synovial fluid glucose to g/dL, divide by 0.0555.

©2007 American Medical Association. All rights reserved.

(Reprinted) JAMA, April 4, 2007—Vol 297, No. 13 1485

#### SEPTIC ARTHRITIS

arthritis (LR, 0.67; 95% CI, 0.43-1.00).<sup>47</sup> Other physical examination findings, such as rigors and sweats, have even lower sensitivity and were not assessed for specificity (Table 3). Similarly, laboratory test results, such as peripheral WBC count, ESR, and CRP, had high sensitivity but very poor specificity.

The history and physical examination are not able to substantially change the pretest probability of septic arthritis in patients with an acutely painful, swollen joint. In most cases, the pretest probability for septic arthritis (range, 8%-27%) is neither sufficiently low nor high enough to direct treatment with confidence. Therefore, arthrocentesis with synovial fluid analysis for WBC count and percentage of polymorphonuclear cells is the best diagnostic tool available for detecting bacterial arthritis while waiting for synovial culture test results.

Synovial fluid glucose, protein, and lactate dehydrogenase are not informative. Other inflammatory markers have been studied but are not readily available to the clinician and therefore were not a focus of our literature search. Assays for cytokines, tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), granulocyte colonystimulating factor, interleukin (IL) 8, IL-6, and IL-1 $\beta$  were examined to see if these markers could differentiate septic arthritis from crystal-associated arthritis, rheumatoid arthritis, reactive arthritis, and lupus. Sensitivity was high with synovial IL-6 and IL-1B performing the best at 100%, but specificity was quite poor for these inflammatory markers, ranging from 3% to 53%. Interestingly, one exception was synovial TNF-α. In the prospective case study by Jeng et al48 of 75 patients presenting to the emergency department with acute arthritis, synovial TNF- $\alpha$  was 95% sensitive and 71% specific for septic arthritis, with an LR of 3.3 (95% CI, 2.1-5.0). Although synovial TNF- $\alpha$  may be helpful in distinguishing between septic arthritis and other inflammatory arthropathies, it cannot be currently recommended without further evidence, and it would need to be readily available.

The reproducibility of the diagnostic value of synovial fluid WBC counts from 4 studies in markedly different clinical environments suggests that the test is simple and generalizable. Results of the arthrocentesis have the potential to change the clinician's management of patients (ie, starting antibiotics). Arthrocentesis is a relatively benign procedure and complications are rare.<sup>12,18,52-54</sup> Patients are likely to achieve substantial benefit from the test, assuming that joint destruction and morbidity can be avoided with early identification of septic arthritis and appropriate treatment.

The main limitations of our study were the lack of high-quality studies among the included studies and the difficulty in establishing an ideal gold standard. Only 3 of 8 studies were rated as level 1 evidence.42,46,48 The limited quality of these studies can affect the reported estimates of diagnostic accuracy in either direction. Also, the use of Gram stain and culture as a gold standard test is problematic because prior studies suggest that the sensitivity of Gram stain is only 29% to 50%, <sup>15,30,44,45,47</sup> and the sensitivity of culture may only be 82%.45 An inadequate gold standard can lead to misclassification of patients with overestimation or underestimation of reported LRs. Currently, the best solution to this problem is to use a combination of Gram stain, culture, and clinical follow-up to detect patients missed by Gram stain and culture alone.

Another significant limitation is the inability to stratify various patient populations within the studies to determine if diagnostic tests operate differently in certain subsets of patients. For example, we were unable to determine if an increased synovial WBC count generates a different LR in patients with septic arthritis who are otherwise well vs patients with chronic rheumatic disease, patients with prosthetic joints, or immunocompromised patients. However, 2 studies did contribute information that these populations are at increased risk. We believe that it is

critically important to ask about these risk factors because their presence will increase the clinician's pretest probability for septic arthritis and therefore generate a different posttest probability.

Although the focus of our study was nongonococcal bacterial arthritis, 3 of the included studies included small numbers of patients with Neisseria gonorrhoeae infectious arthritis (24 of 6242 patients). We recognize that gonococcal arthritis may have different test characteristics than nongonococcal arthritis. However, we do not believe that the inclusion of this small number of patients with N gonorrhoeae infectious arthritis markedly affects the summary LRs that we generated. We do believe it is important for all clinicians to take a detailed sexual history in a patient with an acutely swollen monoarthritis, and to treat for possible N gonorrhoeae in patients with known risk factors.

### SCENARIO RESOLUTION Case 1

The individual presented in the first clinical scenario comes to the emergency department with a monoarticular arthritis of the knee. The differential diagnosis includes septic arthritis vs a flare of her rheumatoid arthritis. The prevalence of septic arthritis in the general population presenting to the emergency department with an acutely swollen and tender joint is approximately 18% (midpoint of the range of prevalence estimates, 8%-27%). Because she has rheumatoid arthritis, she is at increased risk for infection (LR, 2.5; 95% CI, 2.0-3.1) and the prior probability of septic arthritis can be revised to 38%.

There are no physical examination findings or maneuvers, such as range of motion or degree of swelling, that have been studied that can help the clinician discriminate between etiologies of the monoarthritis. Her lack of fever is not reassuring given the poor sensitivity and specificity for septic arthritis. Her peripheral WBC count and ESR are both elevated; however, this

1486 JAMA, April 4, 2007-Vol 297, No. 13 (Reprinted)

may be due to either bacterial arthritis or rheumatoid arthritis.

The synovial WBC count of 48 000/µL has an LR of 2.9 (95% CI, 2.5-3.4) for septic arthritis. Importantly, our review confirms that a low synovial WBC count cannot rule out septic arthritis. A differential for the synovial WBC count should be ordered because if the percentage of polymorphonuclear cells is more than 90%, this will strengthen the clinician's suspicion of bacterial arthritis with an LR of 3.4 (95% CI, 2.8-4.2). Although we do not know if the percentage of polymorphonuclear cells is independently useful when the synovial WBC count is high, her synovial WBC count of 48 000/µL increases the probability from 38% to 64%. The probability of septic arthritis seems high enough and the consequences severe enough that the working diagnosis is septic arthritis, pending the culture test results.

#### Case 2

The patient's risk factors of age older than 80 years (LR, 3.5; 95% CI, 1.8-7.0) and the presence of diabetes mellitus (LR, 2.7; 95% CI, 1.0-6.9) means the probability of septic arthritis is at least 40% if we start with a prior probability of 18%. However, this patient is unlike the general population in that he has a prior clinical diagnosis of gout, and gout is much more common than septic arthritis.<sup>18</sup> When a diagnosis of gout seems likely, most clinicians would start with a lower prior probability for septic arthritis.

Fever is a nonspecific sign that can be observed in many other diseases, such as gout flares. Because there can be concomitant gout and infection,<sup>28,55,56</sup> clinicians must use their judgment to either treat empirically for gout or to obtain synovial fluid to evaluate for septic arthritis, crystalline disease, or both. Many clinicians would recommend performing an arthrocentesis given that establishing a diagnosis of gout in this patient would be helpful for future presentations, and that the consequences of not treating an infected joint can be devastating.

#### **BOTTOM LINE**

When evaluating a patient with a painful, peripheral, swollen joint, the underlying pathology of a monoarthritis may be difficult to diagnose by clinical history and examination alone due to nonspecific symptoms and signs. Identifiable risk factors and the arthrocentesis are most helpful in predicting septic arthritis. In particular, synovial WBC count and percentage of polymorphonuclear cells provide the best utility in identifying septic arthritis while waiting for Gram stain and culture test results. There is no evidence that a patient's symptoms or the physical examination are useful for predicting nongonoccal bacterial arthritis. Future studies should carefully examine the test characteristics of the history, physical examination, and novel synovial fluid laboratory test results to determine if there are any investigative strategies that can provide clinically important benefits for patients with suspected septic arthritis.

Author Contributions: Dr Margaretten had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Margaretten, Kohlwes, Bent. Acquisition of data: Margaretten.

Analysis and interpretation of data: Margaretten, Kohlwes, Moore, Bent.

Drafting of the manuscript: Margaretten.

Critical revision of the manuscript for important intellectual content: Margaretten, Kohlwes, Moore, Bent. Statistical analysis: Margaretten, Moore, Bent. Study supervision: Kohlwes, Bent.

Financial Disclosures: None reported.

Funding/Support: This work was supported by grant 1 K08 ATO1338-01 from the National Center for Complementary and Alternative Medicine (Dr Bent). Role of Sponsors: No funding organizations or sponsors had any role in the design or conduct of the study, in the collection, management, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript.

Acknowledgment: We thank L. Brett Caram, MD, Durham Veterans Administration Medical Center, Duke University Department of Medicine, Durham, NC, and Carrie Tibbles, MD, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Mass, for their review and thoughtful comments to improve earlier versions of the manuscript. No compensation was received for their contributions.

#### REFERENCES

**1.** Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum*. 1998;41:778-799.

2. Baker DG, Schumacher HR Jr. Acute monoarthritis. *N Engl J Med.* 1993;329:1013-1020.

3. Gupta MN, Sturrock RD, Field M. A prospective

2-year study of 75 patients with adult-onset septic arthritis. *Rheumatology (Oxford)*. 2001;40:24-30. **4.** Swan A, Am H, Dieppe P. The value of synovial

fluid assays in the diagnosis of joint disease: a literature survey. *Ann Rheum Dis*. 2002;61:493-498. **5.** Weston VC, Jones AC, Bradbury N, Fawthrop F,

Doherty M. Clinical features and outcome of septic arthritis in a single UK Health District 1982-1991. *Ann Rheum Dis.* 1999;58:214-219.

6. Gupta MN, Sturrock RD, Field M. Prospective comparitive study of patients with culture proven and high suspicion of adult onset septic arthritis. *Ann Rheum Dis.* 2003;62:327-331.

7. Manshady BM, Thompson GR, Weiss JJ. Septic arthritis in a general hospital 1966-1977. *J Rheumatol*. 1980;7:523-530.

**8.** Li SF, Henderson J, Dickman E, Darzynkiewicz R. Laboratory tests in adults with monoarticular arthritis: can they rule out a septic joint? *Acad Emerg Med*. 2004;11:276-280.

**9.** Kaandorp CJ, Krijnen P, Moens HJ, Habbema JD, van Schaardenburg D. The outcome of bacterial arthritis: a prospective community-based study. *Arthritis Rheum*. 1997;40:884-892.

**10.** Morgan DS, Fisher D, Merianos A, Currie BJ. An 18 year clinical review of septic arthritis from tropical Australia. *Epidemiol Infect*. 1996;117:423-428.

 Scopelitis E, Martinez-Osuna P. Gonococcal arthritis. *Rheum Dis Clin North Am*. 1993;19:363-377.
 Sack K. Monarthritis: differential diagnosis. *Am J Med*. 1997;102(suppl 1A):30S-34S.

**13.** Shmerling RH. Synovial fluid analysis: a critical reappraisal. *Rheum Dis Clin North Am*. 1994;20:503-512.

**14.** O'Brien JP, Goldenberg DL, Rice PA. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. *Medicine (Baltimore)*. 1983;62: 395-406.

**15.** McCutchan HJ, Fisher RC. Synovial leukocytosis in infectious arthritis. *Clin Orthop Relat Res.* 1990;(257): 226-230.

 Dubost JJ, Soubrier M, De Champs C, Ristori JM, Bussiere JL, Sauvezie B. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. *Ann Rheum Dis*. 2002;61:267-269.
 Goldenberg DL. Septic arthritis. *Lancet*. 1998;351: 197-202.

**18.** Klippel JH, Weyand CM, Crofford LJ, Stone JH. *Arthritis Foundation: Primer on the Rheumatic Diseases.* 12th ed. Atlanta, Ga: Arthritis Foundation; 2001.

**19.** Bong D, Bennett R. Pseudogout mimicking systemic disease. *JAMA*. 1981;246:1438-1440.

**20.** Masuda I, Ishikawa K. Clinical features of pseudogout attack: a survey of 50 cases. *Clin Orthop Relat Res.* 1988;(229):173-181.

21. Frischnecht J, Steigerwald JC. High synovial fluid white blood cell counts in pseudogout; possible confusion with septic arthritis. *Arch Intern Med.* 1975;135: 298-299.

22. Cathcart ES. Fever and arthritis. Compr Ther. 1979; 5:55-59.

23. Weinberger A, Kesler A, Pinkhas J. Fever in various rheumatic diseases. *Clin Rheumatol*. 1985;4:258-266.

**24.** Rousseau I, Cardinal EE, Raymond-Tremblay D, Beauregard CG, Braunstein EM, Saint-Pierre A. Gout: radiographic findings mimicking infection. *Skeletal Radiol*. 2001;30:565-569.

 Graif M, Schweitzer ME, Deely D, Matteucci T. The septic versus nonseptic inflamed joint: MRI characteristics. *Skeletal Radiol*. 1999;28:616-620.
 Smetana GW, Shmerling RH. Does this patient have temporal arthritis? *JAMA*. 2002;287:92-101.
 Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation? *JAMA*. 1995;273: 313-319.

#### SEPTIC ARTHRITIS

**28.** Yu KH, Luo SF, Liou LB, et al. Concomitant septic and gouty arthritis: an analysis of 30 cases. *Rheumatology (Oxford)*. 2003;42:1062-1066.

 Yu LP, Bradley JD, Hugenberg ST, Brandt KD. Predictors of mortality in non-post-operative patients with septic arthritis. *Scand J Rheumatol*. 1992;21:142-144.
 Faraj AA, Omonbude OD, Godwin P. Gram staining in the diagnosis of acute septic arthritis. *Acta Orthop Belg*. 2002;68:388-391.

**31.** Brandt KD, Cathcart ES, Cohen AS. Gonococcal arthritis: clinical features correlated with blood, synovial fluid and genitourinary cultures. *Arthritis Rheum*. 1974;17:503-510.

**32.** Ross JJ, Shamsuddin H. Sternoclavicular septic arthritis: review of 180 cases. *Medicine (Baltimore)*. 2004;83:139-148.

**33.** Ryan MJ, Kavanagh R, Wall PG, Hazleman BL. Bacterial joint infections in England and Wales: analysis of bacterial isolates over a four year period. *Br J Rheumatol*. 1997;36:370-373.

**34.** Peters RH, Rasker JJ, Jacobs JW, Prevo RL, Karthaus RP. Bacterial arthritis in a district hospital. *Clin Rheumatol*. 1992;11:351-355.

**35.** Freed JF, Nies KM, Boyer RS, Louie JS. Acute monoarticular arthritis: a diagnostic approach. *JAMA*. 1980; 243:2314-2316.

**36.** Sharma M, Leirisalo-Repo M. Arthritis patient as an emergency case at a university hospital. *Scand J Rheumatol.* 1997;26:30-36.

Hsieh YS, Yang SF, Lue KH, Lu KH. Clinical correlation with the PA/plasmin system in septic arthritis of the knee. *Clin Orthop Relat Res.* 2006;447:172-178.
 Goldenberg DL, Cohen AS. Synovial membrane

histopathology in the differential diagnosis of rheumatoid arthritis, gout, pseudogout, systemic lupus erythematosus, infectious arthritis and degenerative joint disease. *Medicine (Baltimore)*. 1978;57:239-252. **39.** Gratacós J, Vila J, Moya F, et al. D-lactic acid in synovial fluid: a rapid diagnostic test for bacterial synovitis. *J Rheumatol*. 1995;22:1504-1508.

40. Brook I, Reza MJ, Bricknell KS, Bluestone R, Finegold SM. Synovial fluid lactic acid: a diagnostic aid in septic arthritis. *Arthritis Rheum*. 1978;21:774-779.
41. Mossman SS, Coleman JM, Gow PJ. Synovial fluid lactic acid in septic arthritis. *N Z Med J*. 1981;93:115-117.

**42.** Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA. Risk factors for septic arthritis in patients with joint disease: a prospective study. *Arthritis Rheum.* 1995;38:1819-1825.

**43.** Saraux A, Taelman H, Blanche P, et al. HIV infection as a risk factor for septic arthritis. *Br J Rheumatol*. 1997;36:333-337.

44. Söderquist B, Jones I, Fredlund H, Vikerfors T. Bacterial or crystal-associated arthritis? discriminating ability of serum inflammatory markers. *Scand J Infect Dis*. 1998;30:591-596.

45. Krey PR, Bailen DA. Synovial fluid leukocytosis: a study of extremes. *Am J Med.* 1979;67:436-442.
46. Shmerling RH, Delbanco TL, Tosteson AN, Trentham DE. Synovial fluid tests: what should be ordered? *JAMA.* 1990;264:1009-1014.

**47.** Kortekangas P, Aro HT, Tuominen J, Toivanen A. Synovial fluid leukocytosis in bacterial arthritis vs. reactive arthritis and rheumatoid arthritis in the adult knee. *Scand J Rheumatol.* 1992;21:283-288.

**48.** Jeng GW, Wang CR, Liu ST, et al. Measurement of synovial tumor necrosis factor-alpha in diagnosing emergency patients with bacterial arthritis. *Am J Emerg Med.* **1997**;**15**:626-629.

**49.** Schlapbach P, Ambord C, Blochlinger AM, Gerber NJ. Bacterial arthritis: are fever, rigors, leucocytosis and blood cultures of diagnostic value? *Clin Rheumatol.* 1990;9:69-72.

**50.** Rosenthal J, Bole GG, Robinson WD. Acute nongonococcal infectious arthritis: evaluation of risk factors, therapy, and outcome. *Arthritis Rheum*. 1980;23: 889-897.

**51.** Deesomchok U, Tumrasvin T. Clinical study of culture-proven cases of non-gonococcal arthritis. *J Med Assoc Thai.* 1990;73:615-623.

**52.** Schumacher HR Jr. Arthritis of recent onset: a guide to evaluation and initial therapy for primary care physicians. *Postgrad Med.* 1995;97:52-54, 57-59. 63.

**53.** Till SH, Snaith ML. Assessment, investigation, and management of acute monoarthritis. *J Accid Emerg Med.* 1999;16:355-361.

**54.** Thumboo J, O'Duffy JD. A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium. *Arthritis Rheum*. 1998;41:736-739.

**55.** Lee CH, Chen YJ, Ueng SW, Hsu RW. Septic arthritis of the ankle joint. *Chang Gung Med J*. 2000;23: 420-426.

**56.** Jones A, Henderson MJ, Berman P, Doherty M. Septic arthritis complicating apatite associated destructive arthropathy. *Ann Rheum Dis.* 1990;49:1005-1007.